One has to wonder who checks the costing that Novartis uses to justify the price of its Kymriah Cancer Drug. What would Robert Koch, Louis Pasteur or Alexander Fleming make of this behaviour?
https://www.bloomberg.com//news/articles/2017-08-30/cancer-breakthrough-heralds-new-era-of-cures-costs-and-choices
My Weekly Reading for December 22, 2024
-
Learning Fiscal Discipline: Colorado’s Success, Shortcomings, and
Regulatory Ruse
Excerpt:
At its core, TABOR codifies limits on both taxation and sp...
41 minutes ago
No comments:
Post a Comment